CASI Pharmaceuticals (CASIF) Gross Margin (2022 - 2025)
CASI Pharmaceuticals (CASIF) reported Gross Margin of 51.14% for Q4 2025, up 2697.0% on a YoY basis from 1.83% in Q4 2024, and up 122.72% quarter-over-quarter from 22.96% in Q3 2025.
CASI Pharmaceuticals (CASIF) Gross Margin (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals has reported Gross Margin for 4 years, with the latest figure at 51.14% in Q4 2025.
- For the quarter ending Q4 2025, Gross Margin rose 2697.0% year-over-year to 51.14%; the trailing twelve-month figure through Dec 2025 stood at 48.65% (up 959.0% YoY), and the FY2025 full-year result was 48.65%, up 959.0% from the prior year.
- Gross Margin for Q4 2025 stood at 51.14%, up from 22.96% in the prior quarter.
- The five-year high for Gross Margin was 107.1% in Q4 2022, with the low at 22.96% in Q3 2025.
- Historically, Gross Margin has averaged 55.13% across 4 years, with a median of 58.21% in 2022.
- Annual changes were most pronounced in 2023 — Gross Margin sank 4805 bps — and 2025, when it surged 2697 bps.
- CASI Pharmaceuticals' Gross Margin stood at 107.1% in 2022, then plunged by 45 bps to 59.05% in 2023, then sank by 59 bps to 24.17% in 2024, then jumped by 112 bps to 51.14% in 2025.
- The last three Gross Margin figures came in at 51.14% (Q4 2025), 22.96% (Q3 2025), and 49.29% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 860,679.92 Bn | 860,679.89 Bn | - | - |
| 2 | Belite Bio | 55,284.00 Bn | 55,284.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,206.94 Bn | 16,206.93 Bn | - | - |
| 4 | Legend Biotech | 3,318.00 Bn | 3,317.71 Bn | 242.10 Mn | 79.04% |
| 5 | Akari Therapeutics | 1,543.84 Bn | 1,543.84 Bn | - | - |
| 6 | Evaxion A | 1,449.11 Bn | 1,449.09 Bn | - | - |
| 7 | Psyence Biomedical | 216.99 Bn | 216.98 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 115.22 Bn | 107.97 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 90.58 Bn | 90.58 Bn | - | - |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn | 51.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 51.14% |
| Sep 30, 2025 | 22.96% |
| Jun 30, 2025 | 49.29% |
| Mar 31, 2025 | 58.00% |
| Dec 31, 2024 | 24.17% |
| Sep 30, 2024 | 51.91% |
| Jun 30, 2024 | 51.95% |
| Mar 31, 2024 | 52.98% |
| Dec 31, 2023 | 59.05% |
| Sep 30, 2023 | 58.72% |
| Jun 30, 2023 | 59.41% |
| Mar 31, 2023 | 59.53% |
| Dec 31, 2022 | 107.10% |
| Sep 30, 2022 | 58.42% |
| Jun 30, 2022 | 58.75% |
| Mar 31, 2022 | 58.77% |